| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39820 | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jan, 2018
(6 years ago) | |
| US7642268 | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Sep, 2021
(2 years ago) | |
| US7309707 | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Sep, 2021
(2 years ago) | |
| US6908928 | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Sep, 2021
(2 years ago) | |
| US6777423 | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Sep, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5478578 | BOEHRINGER INGELHEIM | Powders for inhalation |
Dec, 2012
(11 years ago) | |
|
USRE39820 (Pediatric) | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jul, 2018
(5 years ago) | |
| USRE38912 | BOEHRINGER INGELHEIM | Process for preparing powder formulations |
Oct, 2021
(2 years ago) | |
| US7070800 | BOEHRINGER INGELHEIM | Inhalable powder containing tiotropium |
Jan, 2022
(2 years ago) | |
|
US6908928 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Mar, 2022
(2 years ago) | |
|
US7642268 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Mar, 2022
(2 years ago) | |
|
US6777423 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Mar, 2022
(2 years ago) | |
|
US7309707 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Mar, 2022
(2 years ago) | |
|
USRE38912 (Pediatric) | BOEHRINGER INGELHEIM | Process for preparing powder formulations |
Apr, 2022
(2 years ago) | |
|
US7070800 (Pediatric) | BOEHRINGER INGELHEIM | Inhalable powder containing tiotropium |
Jul, 2022
(1 year, 9 months ago) | |
| US8022082 | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jan, 2026
(1 year, 8 months from now) | |
|
US8022082 (Pediatric) | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jul, 2026
(2 years from now) | |
| US7694676 | BOEHRINGER INGELHEIM | Dry powder inhaler |
Mar, 2027
(2 years from now) | |
|
US7694676 (Pediatric) | BOEHRINGER INGELHEIM | Dry powder inhaler |
Sep, 2027
(3 years from now) | |
| US9010323 | BOEHRINGER INGELHEIM | Inhaler and sieve for an inhaler |
Apr, 2030
(5 years from now) | |
Spiriva is owned by Boehringer Ingelheim.
Spiriva contains Tiotropium Bromide.
Spiriva has a total of 20 drug patents out of which 15 drug patents have expired.
Expired drug patents of Spiriva are:
- US5478578
- USRE39820*PED
- USRE38912
- US7070800
- US6908928*PED
- US7642268*PED
- US6777423*PED
- US7309707*PED
- USRE38912*PED
- US7070800*PED
- USRE39820
- US7642268
- US7309707
- US6908928
- US6777423
Spiriva was authorised for market use on 30 January, 2004.
Spiriva is available in powder;inhalation dosage forms.
Spiriva can be used as for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema, administration of an inhalable powder comprising tiotropium via device.
The generics of Spiriva are possible to be released after 19 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-89) | Dec 17, 2012 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inha...
Dosage: POWDER;INHALATION
SPIRIVA family patents
